Catalyst Dossier · compiled by CeliA 🧫
Novartis AG (NVS)
Pharmaceutical Preparations · market cap $284.2B · as of 2026-07-08
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Novartis AG (NVS) is a Swiss multinational pharmaceutical giant, ranked eighth globally by revenue in 2024, with a market cap of approximately $284 billion and roughly 75,900 employees. The company carries a broad late- and mid-stage pipeline spanning oncology, ophthalmology, immunology, and cardiovascular disease, with the nearest high-importance catalysts being Phase 2 and Phase 3 readouts for Remibrutinib expected around July 23, 2026. Recent trial activity has skewed positive, with multiple Phase 2 and Phase 3 outcomes reported as positive in June 2026.
The catalyst path
- 2026-10-15 (est.)Phase 2 · Bicalutamideimp 7/10
- 2026-12-23 (est.)Phase 2 · AAA517imp 7/10
- 2026-12-30 (est.)Phase 2 · Lutetium Lu 177 Vipivotide Tetraxetanimp 7/10
- 2026-12-31 (est.)Phase 2 · asciminibimp 7/10
- 2027-01-01NDA Filingimp 7/10
- 2027-01-01 (est.)Phase 2 · dabrafenib/trametinibimp 7/10
- 2027-01-25 (est.)Phase 2 · TNO155imp 7/10
- 2027-01-29 (est.)Phase 2 · QCZ484imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Alcohol-free dexamethasone mouth rinse (Stomatitis sub-study) | Phase 2 | Hormone Receptor Positive Breast Cancer |
| Certican® | Phase 3 | Renal Interstitial Fibrosis |
| Verteporfin PDT | Phase 3 | Pathological Myopia |
| Conventional Therapy | Phase 2 | Non-infectious Intermediate Uveitis |
| lisinopril | Phase 3 | Hypertension |
| Benazepril plus hydrochlorothiazide | Phase 3 | Hypertension |
| [68Ga]Ga-PSMA-11 | Phase 3 | Prostatic Neoplasms |
| SoC (Coartem) | Phase 2 | Uncomplicated Plasmodium Falciparum Malaria |
| Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008 | Phase 2 | Influenza |
| Calcium and vitamin D supplements | Phase 3 | Paget's Disease of Bone |
| Meningococcal (group B) multicomponent recombinant adsorbed vaccine. | Phase 2 | Meningococcal Disease |
| Dovitinib and docetaxel | Phase 2 | Gastric Cancer |
| dabrafenib/trametinib | Phase 2 | Anaplastic Thyroid Cancer |
| QAU145 | Phase 2 | Cystic Fibrosis |
| AIN457 300 mg | Phase 3 | Chronic Plaque Type Psoriasis |
| GSK2110183 (afuresertib) | Phase 2 | Cancer |
| Octreotide (Immediate release) | Phase 2 | Peritoneal Neoplasms |
| TMZ | Phase 2 | Medulloblastoma |
| QAV680 | Phase 2 | Seasonal Allergic Rhinitis |
| Midostaurin (PKC412) | Phase 2 | Leukemia |
Price & technical context
3-month
-4.6%
6-month
-5.3%
12-month
+14.8%
52-wk range
$121.80–$168.62
vs 50-day MA
-7.9%
vs 200-day MA
-6.5%
Realized vol
28.2%
Max drawdown
-18.9%
Daily closes through 2026-09-18. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for NVS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.